Functional availability of gamma-herpesvirus K-cyclin is regulated by cellular CDK6 and p16INK4a

Hidenori Yoshioka1, Kohji Noguchi, Kazuhiro Katayama

  • 1Division of Chemotherapy, Faculty of Pharmacy, Keio University, 1-5-30 Shiba-koen, Minato-ku, Tokyo 105-8512, Japan.

Insights

Viral K-cyclin stability is regulated by CDK6 binding and p16INK4a. CDK6 binding stabilizes K-cyclin, while its absence targets it for proteasomal degradation, impacting human cell function.

Area of Science:

  • Molecular Biology
  • Virology
  • Cell Biology

Background:

  • Kaposi's sarcoma-associated herpesvirus (KSHV) encodes viral K-cyclin, homologous to mammalian D-type cyclins.
  • Understanding K-cyclin's regulatory mechanisms is crucial for comprehending viral pathogenesis and host cell cycle control.

Purpose of the Study:

  • To elucidate the regulatory mechanisms governing K-cyclin function and degradation in human cells.
  • To investigate the roles of CDK6 and p16INK4a in K-cyclin stability and activity.

Main Methods:

  • Utilized human embryonic kidney (HEK293) and primary effusion lymphoma (JSC-1) cell lines.
  • Employed proteasome inhibitor MG132 to assess K-cyclin ubiquitination and degradation.
  • Investigated the effects of CDK6 co-expression and p16INK4a silencing on K-cyclin stability and complex formation.

Main Results:

  • Proteasome inhibition (MG132) led to K-cyclin ubiquitination.
  • CDK6 co-expression prevented K-cyclin ubiquitination, stabilizing the protein.
  • K-cyclin mutants unable to bind CDK6 were degraded via the proteasome.
  • p16INK4a silencing enhanced K-cyclin-CDK6 complex formation and kinase activity.

Conclusions:

  • CDK6-bound K-cyclin is functionally stable, whereas monomeric K-cyclin undergoes ubiquitin-dependent degradation.
  • The balance between CDK6 and p16INK4a critically regulates the availability of functional K-cyclin in human cells.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...